Powered by

Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer

Jun 08, 2020 - PR Newswire
Board and Executive Moves

PR Newswire

 Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the appointment of Justin Renz to the position of Chief Financial Officer. Mr. Renz, a highly accomplished leader with over 20 years of experience in the biopharmaceutical industry, brings an extensive array of financial and operational experience to Ardelyx.